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Abstract
The proteins MUC18 and Mader have been identified as markers of tumor
progression in melanoma cells. MUC18, also known as MCAM (melanoma
cell adhesion molecule) and as CD146 (endothelial antigen), is a cell adhesion
molecule belonging to the immunoglobulin superfamily. Mader is a transcrip-
tional regulator shown to negatively regulate EGR-1. As it is known that neo-
plastic cells of neuroectodermal origin frequently express neuron-specific mol-
ecules, we studied whether these melanoma-associated antigens are found in
normal CNS tissue. We investigated the expression of MUC18/MCAM and
Mader in adult human post mortem CNS tissue by immunohistochemistry,
immunoblot and two-dimensional gel electrophoresis. Our results show that
Mader is preferentially expressed on neurons and glial cells and that the adhe-
sion protein MUC18/MCAM is mainly expressed on vasculature within the
CNS. These observations may have important implications for further studies
investigating their possible roles in cell adhesion and proliferation control
within the CNS.
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Introduction
Tumors of neuroectodermal origin are known to ex-
press neuron-related proteins that are undetectable in the
tissue prior to malignant transformation. A typical exam-
ple of this phenomenon is the expression of neuron-spe-
cific enolase (NSE) and neural cell adhesion molecule (N-
CAM) in small cell lung carcinoma [1]. Detection of these
proteins is important for diagnosis and prognosis of small
cell lung carcinoma. At the same time, these molecules are
known to be involved in the normal functions of nervous
tissue. This raises the question of whether additional pro-
teins that are identified as markers in neoplastic processes
on neuroectodermal cells might also be expressed on nor-
mal CNS tissue. In a preliminary study, we had analyzed
the expression of the melanoma-associated molecule
MUC18 using two monoclonal antibodies (MAbs) MUC-
BA18.3 and MUCBA18.4 by immunoblot [2]. Since
MUCBA18.3 cross-reacts with a second protein, called
Mader, we now focused on MUC18 and Mader expres-
sion in central nervous tissue.
The MUC18 glycoprotein was first described by Leh-
mann et al. [3] as an integral membrane protein of 113 kD
belonging to the immunoglobulin superfamily [4]. In be-
nign melanocytic nevi and thin primary melanomas,
MUC18 could be detected only sporadically. However,
with increasing tumor thickness, MUC18 expression be-
comes more frequent and is found in 80% of advanced
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primary tumors and metastases, so that its expression cor-
relates with a poor prognosis and the occurrence of metas-
tasis. Occurrence of MUC18 in non-malignant tissues has
been observed in smooth muscle and endothelia of several
peripheral organs [5, 6]. An immunoreactivity of human
cerebellar tissue has also been described, but the identifi-
cation of MUC18-expressing cells was not possible [6].
Recent studies have shown that MUC18 functions as a
cell adhesion molecule (melanoma cell adhesion mole-
cule, MCAM), interacting with an as yet unidentified
ligand [6, 7]. Pickl et al. [8] demonstrated that MUC18/
MCAM can be induced on all T cells after stimulation.
Mader was first detected by the antibody MUCBA-
18.3, which cross-reacts with both Mader and MUC18
[9]. Mader is a highly conserved cytoplasmic and nuclear
protein with a molecular weight of approximately 65 kD
that belongs to the set of growth-factor-induced delayed
early response genes. Recent findings have shown that
Mader is identical to a negative regulator of Egr-1 (NAB-
2) which is a transcription factor that directs expression of
several genes involved in cell proliferation [10]. Mader is
strongly expressed in malignant melanoma, but has not
been detected in other tissues, including epidermis and
gastrointestinal tract.
In addition to these two novel proteins, the intercellu-
lar adhesion molecule ICAM-1 was found to be associated
with the development of metastasis in malignant melano-
ma [11, 12]. ICAM-1 can be expressed in a great number
of cell types. ICAM-1 expressed by endothelia is involved
in the migration and extravasation of T cells [13, 14], and
its expression on neurons and astroctyes enables T cells
and monocytes to bind to these cells in the brain paren-
chyma [15, 16]. Increased expression of ICAM-1 has been
found after ischemia in the cortex [17] as well as in Alz-
heimer’s disease, where expression of ICAM-1 on a subset
of astroctyes was found to be increased [18].
N-CAM plays an important role in CNS development,
directing cell migration and axon outgrowth, as has been
shown in vitro and in vivo developmental studies [19, 20].
In healthy adult humans, N-CAM isoforms are selectively
found on neurons, glial cells, skeletal muscle and natural
killer cells. N-CAM, like ICAM-1 and MUC18, belongs to
the immunoglobulin superfamily. Although NSE is, as the
name indicates, normally expressed exclusively on neu-
rons and APUD (amin precursor uptake and decarboxyla-
tion) cells, it appears on neuroectodermal cells after ma-
lignant transformation [21, 22].
In the present study, we investigated the presence of
MUC18/MCAM and Mader in mature human CNS fron-
tal lobe tissue from postmortem brains using immunohis-
Table 1. Characterization of post mortem brains used in this
study
Patient
No.
Sex Age
years
Cause of death Post mortem
interval
male 22 accident 8
2 female 56 suicide 5
3 female 25 intoxication 5
4 male 60 heart attack 3
5 male 30 homicide 9
6 female 27 suicide 3
7 male 35 suicide 4
8 male 47 suicide 2
9 female 37 suicide 4
10 female 54 suicide 2
tochemistry, immunoblotting and two-dimensional elec-
trophoresis and compared the protein expression patterns
with those of the adhesion molecules N-CAM and
ICAM-1 as well as NSE.
Materials and Methods
Cells, Tissues and Preparation of Brain Homogenates
After exclusion of pathological findings, 10 brains examined by a
pathologist during autopsy were used in this study. The characteris-
tics of the donors of frontal lobe tissues are given in table 1. At autop-
sy, the samples were prepared, frozen in liquid nitrogen and stored at
–196°C within 2–9 h after death.
The human melanoma cell line Mel Juso was maintained as
described [23]. The dissected CNS tissues (1-cm3 pieces) were
homogenized in ice in 10% sucrose in 0.05 M Tris HCl buffer,
pH 7.8, containing 1 mM PMSF and 1.5% Triton X-100.
SDS-PAGE
Brain homogenate was centrifuged at 20,000 g for 60 min. Ali-
quots of the supernatant containing 5 Ìg of protein were heated in
equal volumes of SDS sample buffer containing 0.5% dithiothreitol.
After cooling, 0.5 Ìg dithiothreitol was added to a sample volume of
100 Ìl to avoid reaggregation of the polypeptides. To detect possible
postmortem degradation products or alterations in electrophoretic
migration of the detected proteins following autopsy and tissue incu-
bation and preparation, we conducted preliminary experiments. Hu-
man brain tissue was investigated at different preparation times after
death by SDS-PAGE.
Two-Dimensional Gel Electrophoresis
Solid urea was added to aliquots of brain homogenate containing
45 Ìg of protein to give 9.5 M solution. Samples were then solubi-
lized by addition of an equal volume of lysis buffer [24]. Centrifuga-
tion was carried out at 20,000 g for 60 min and the supernatants used
for two-dimensional PAGE.
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Western Blot Analysis and Immunodetection
Semidry blotting of the separated proteins onto polyvinyldifluo-
ride membranes (Biorad, Munich) was performed in a discontinuous
buffer system at a constant voltage of 60 V and 1.7 mA/cm2 for
150 min without additional cooling. After blocking with 5% nonfat
dried milk in TTBS the membranes were incubated overnight with
the different primary antibodies (diluted 1:50 in TTBS). Membranes
were then incubated with biotinylated goat anti-rabbit immunoglob-
ulin as secondary antibody (1:3,000 in TTBS) for 90 min. The mem-
branes were washed and then incubated for 90 min with streptavid-
in-alkaline phosphatase (1:3,000 in TTBS). The color was developed
by immersing the membranes in a 1% solution of BCIP and NBT as
chromogen substrates in 0.1 M Tris, 0.05 mM MgCl2, pH 9.5.
Immunohistochemistry
Small blocks of the frozen samples were sectioned into 7-Ìm-
thick serial sections, air dried overnight at 4°C and then fixed in
acetone for 10 min at 4°C. Endogenous peroxidase activity was
quenched by treatment with 3% H2O2 for 10 min at 4°C and nonspe-
cific binding blocked with 1% bovine serum albumin (Sigma, St.
Louis, Mo., USA) for 20 min at room temperature. The first investi-
gations were done by the avidin-biotin complex (ABC) method with
a counterstaining of the nuclei by hematoxylin. A monoclonal IgG
directed against an Aspergillus niger enzyme (DAKO, Denmark) was
used for negative control. To allow a better identification of location
of the stained structures, a double-staining technique using two
MAbs was established. The ABC method was combined with the
alkaline phosphatase-antialkaline phosphatase (APAAP) method
and followed by a hematoxylin counterstaining. Although the two
primary antibodies were of the same species, the system could be
optimized to eliminate any cross-reactivity between the two staining
systems. Slides showing localization of different epitopes in different
cells indicate a good specificity of this double-staining technique.
The two staining procedures were done after each other, so that the
first primary antibody was no longer detectable by the secondary
antibody of the second staining. This specificity was only achievable
when the ABC staining was done first. The following steps were car-
ried out at room temperature, and the sections were washed 3 times
for 3 min in 0.05 M TBS (pH 7.6) after each incubation step. The
sections were incubated in the first primary antibody, diluted 1:250
in TBS with 1% BSA for 30 min. The first secondary antibody [bioti-
nylated rabbit anti-mouse-F(ab))2; DAKO, Hamburg, Germany] was
diluted 1:250 in TBS containing 1% rabbit serum (DAKO), and the
sections incubated for 30 min. Horseradish-peroxidase-coupled
streptavidin (1:750 in TBS, DAKO) was added for 30 min followed
by diaminobenzidine substrate for 5 min (Sigma; 10 mg in 15 ml
TBS). Counterstaining as described below or incubating with anti-
body directed against a second antigen was done afterwards. Follow-
ing 45 min of incubation with the second primary antibody, the rab-
bit anti-mouse bridge antibody (1:30 in TBS rabbit serum, DAKO)
was added for 30 min followed by the APAAP complex (1:25,
30 min, DAKO). The reaction was developed using new fuchsin
(5 min, DAKO). The nuclei were counterstained using hematoxylin
(3 min), and the sections were embedded in Kaiser’s glycerinated
gelatin and evaluated with a Zeiss-Optiplan microscope. Cells which
had bound the first primary antibody stained brown, while those
which bound the second primary antibody stained red. Staining with
the anti-Mader antibodies was performed using a carbazole substrate
as described [9].
Antibodies
MAbs MUCBA18.3 (IgG1) and MUCBA18.4 (IgG1) were pro-
duced against purified, denatured MUC18 antigen as described [4].
MAb MUCBA18.4 recognizes an extracellular epitope of the
MUC18 glycoprotein. MAb MUCBA18.3 recognizes both the pro-
tein Mader and an intracellular epitope of MUC18. These hybrido-
ma culture supernatants were diluted 1:10. The anti-MUC18 anti-
body A32 (IgG1; [6]) was kindly provided by M. Herlyn, Wistar
Institute, Philadelphia, Pa., USA, as ascites and was used at a dilu-
tion of 1:500. MAb A32 reacts with an extracellular epitope distinct
from that recognized by MUC18BA4. The anti-Mader antibodies
5H1 and 1C4 (both IgG1) were produced against recombinant Mad-
er protein as described [9] and were used as undiluted culture super-
natants.
Additional primary MAbs included: anti-human NSE (IgG1,
clone DAKO-NSE H14, DAKO) diluted 1:50; anti-human N-CAM
(DAKO) diluted 1:500; anti-human I-CAM-1 (IgG1, clone BBIG-I1,
R & D Systems, Minneapolis, Minn., USA) diluted 1:200; anti-
human CD31 (IgG1, clone JC/70A, DAKO) diluted 1:25; anti-A. nig-
er glucose oxidase (IgG1, clone DAK-GO1, DAKO) as a negative
control diluted as the compared anti-human monoclonals.
As secondary antibodies we used: biotinylated rabbit anti-mouse
immunoglobulin diluted 1:200; biotinylated rabbit anti-mouse im-
munoglobulin [F(ab))2 fragment], diluted 1:250; rabbit anti-mouse
immunoglobulin (for APAAP) diluted 1:30. All secondary antibodies
were obtained from DAKO. Peroxidase-conjugated streptavidin (di-
luted 1:750) and murine APAAP complex (diluted 1:30) were also
obtained from DAKO.
Results
Immunohistochemical Analysis of MUC18 and Mader
Expression in Brain Tissue
Frontal lobe brain tissue was examined for the expres-
sion of the cell adhesion molecule MUC18/MCAM and of
the N-CAM and the inducible leukocyte binding adhesion
molecule ICAM-1. Neuronal cells were identified by
staining for NSE, and vascular endothelia were identified
using an antibody to CD31. CD31 was found to be
expressed on endothelial cells of all vessels but was not
observed on any other cells in the brain tissue. ICAM-1
expression was noted on endothelial cells of the vascula-
ture except in capillaries and also on cells surrounding
those blood vessels. Additionally, some cells in the brain
parenchyma apart from the blood vessels also showed
positive reaction (fig. 1). N-CAM expression was ob-
served throughout the examined brains.
MAbs MUCBA18.3, MUCBA18.4, and A32 directed
to the protein MUC18/MCAM reacted with endothelial
cells of the vasculature. Double staining with CD31 indi-
cated that the endothelial cells of blood vessels showing a
muscular layer, but not capillaries, were MUC18/MCAM
positive (fig. 2). In contrast to the uniform staining pat-
MUC18/MCAM and Mader in
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Fig. 1. Frozen section from human frontal lobe tissue (brain No.
6). Immunostaining with antibody to ICAM-1 shows reactive cells in
blood vessels greater than capillaries and in the surrounding of these
vessels. Additionally, there are some reactive cells stained in the
brain parenchyma, possibly indicating ICAM-1-positive astrocytes
or microglial cells. DAB = brown color. !160.
Fig. 2. Frozen section from human frontal lobe tissue (brain No.
4). The double staining with antibodies to MUCBA18.3 (DAB =
brown color) and CD31 PECAM (newfuchsin = red color) shows
reaction to MUCBA18.3 only in blood vessels greater than capillaries
and additionally on cells in the brain parenchyma. !100.
Fig. 3. Serial section of the same sample as shown in figure 1.
Immunostaining with antibody to MUCBA18.4 (DAB = brown col-
or). Mainly the pre- and postcapillary blood vessels are stained, but
there are also some reactive cells in the brain parenchyma away from
the vasculature. !160.
Fig. 4. Frozen section from human frontal lobe tissue (brain No.
8). Immunostaining with antibodies to NSE (DAB = brown color)
and MUCBA18.3 (newfuchsin = red color). The neuron shown is
positive for both NSE and MUCBA18.3. !1,600.
tern of the three anti-MUC18 antibodies on the vascula-
ture, distinct patterns of reactivity were observed on non-
vascular elements in the brain tissue.
While reactivity with MUCBA18.4 and A32 was main-
ly seen on vascular elements in the brain samples and only
sporadically detected on parenchyma cells away from the
vasculature (fig. 3), MUCBA18.3 was observed to react
with a higher proportion of parenchymal cells. Double
staining with the antibody to NSE identified most of these
cells as neurons. The MUCBA18.3-expressing neurons
accounted for less than 25% of the NSE-positive cells in
all brains examined (fig. 4). In addition some NSE-nega-
tive cells – thought to be glial cells – were also reactive.
Although a few cells reacted with both MUCBA18.3 and
anti-N-CAM, most cells reacted with either MUCBA18.3
or with anti-N-CAM. As shown in figure 5, the anti-Mad-
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Fig. 5. Expression of Mader protein. A Frozen section from human frontal lobe tissue (brain No. 10) stained with
the anti-Mader MAb 5H1 (1:400). Red staining of several cells can be seen. B Similar section stained with the
MUC18-specific MAb A32 (1:400).
Fig. 6. Immunoblot with MAb MUCBA18.3 following SDS-
PAGE. Lanes 1 and 10 = Biotinylated marker proteins; lanes 2 and 9
= melanoma cell line Mel Juso; lanes 3–8 = postmortem frontal lobe
tissue. Arrows indicate molecular weights 65 and 113 kD.
Fig. 7. Two-dimensional PAGE gel electrophoresis of a frontal
lobe homogenate incubated with the MUCBA18.3 antibody showing
proteins in isoelectric range of pH 5.9–8 at molecular weights of 65
and 113 kD (arrows).
er MAb 5H1 also stained many of the cells in these
forebrain sections, suggesting that a portion of the
MUCBA18.3 reactivity reflects Mader expression. These
staining patterns were seen in all investigated brains.
Western Blot Analysis of Anti-MUC18-Reactive
Proteins
Experiments at different times before tissue prepara-
tion and incubation after death revealed no alterations in
electrophoretic migration patterns of the protein bands
detected by the MAbs used. Therefore, postmortem deg-
radation artifacts could be excluded.
It is known that MAb MUC18BA.4 reacts only with
MUC18 while BA.3 detects both the 113-kD glycoprotein
MUC18 and the 65-kD protein Mader. The broader
immunoreactivity of MUC18BA.3 raised the question of
whether this antibody is detecting Mader, or an additional
cross-reactive protein in brain parenchyma. In order to
A B
MUC18/MCAM and Mader in
Human CNS
Neuroimmunomodulation 1998;5:270–276 275
examine this, proteins in the brain samples were sepa-
rated by SDS-PAGE, blotted onto nitrocellulose and incu-
bated with the anti-MUC18 MAbs. Incubation with MAb
MUCBA18.4 revealed a single band with an Mr of
113 kD, consistent with the Mr of the MUC18 glycopro-
tein isolated from human melanoma cells. However, incu-
bation with MAb MUCBA18.3 revelaed a strong band
with the 65-kD Mr of Mader in addition to the 113-kD
band (fig. 6). Discrete additional protein bands of molec-
ular weights between Mr 66–97 kD were seen in both
MUCBA18.4 and MUCBA18.3 blots, presumably repre-
senting postmortem degradation products of MUC18. In
lysates of the melanoma cell line Mel Juso (fig. 6, lanes 2
and 9) the predominant 113-kD band of MUC18 as well
as the band in the 65-kD area can be seen. Western blot-
ting of the two-dimensional PAGE-separated brain pro-
teins revealed reactivity of MAb MUCBA18.3 with pro-
teins in the isoelectric range between pH 5.9–8 at the
observed molecular weights (fig. 7).
Discussion
Initially MUC18/MCAM and Mader were identified
as human-melanoma-associated antigens [3, 9]. Since
MUC18/MCAM and Mader expressions are common in
tumors of neuroectodermal origin, e.g. melanomas, glio-
mas and neuroblastomas, it was feasible that these mole-
cules might also be expressed in some areas of the brain.
In fact Shih et al. [6] reported MUC18 expression in
human cerebellum, detectable with MAb A32. However,
the type of cells expressing MUC18 in cerebellum could
not be identified. Mader expression has not yet been
examined on normal human CNS tissue. In this study, we
have examined MUC18/MCAM as well as Mader expres-
sion in forebrain samples. Because of its structural simi-
larities belonging to the immunoglobulin superfamily, we
compared MUC18 expression with those of ICAM-1 and
N-CAM.
In our material three MAbs, which are directed at dis-
tinct MUC18 epitopes, reacted with blood vessels con-
firming that this molecule is strongly expressed in the
endothelium of some pre- and postcapillary vessels.
ICAM-1 was found to be expressed in the vasculature in
the CNS in a similar way. Comparison of the staining pat-
terns with the specific endothelial marker CD31 showed
that only endothelium of blood vessels larger than capil-
laries express ICAM-1. N-CAM expression was examined
throughout the brain parenchyma, and no relationship
was found to ICAM-1 or to MUC18/MCAM. It is known,
that ICAM-1 is an endothelial CAM that enables leuko-
cytes to migrate through the vessel wall and mediates
adhesion to astrocytes and neurons [15, 16]. The sporadi-
cally seen anti-ICAM-1-reactive cells in the brain paren-
chyma apart from the blood vessels could reflect ICAM-
1-expressing glial cells. ICAM-1 expression by astrocytes
and microglia has already been described on primary cells
of rats [25]. The staining pattern of antibodies to ICAM-1
parallels that of MUCBA18.4, also in sporadically detect-
able anti-MUCBA18.4-reactive cells in the brain paren-
chyma. This underlines the hypothesis of similar expres-
sion of ICAM-1 and MUC18/MCAM in the CNS. Given
that these molecules have similar structures [4] and ex-
pression patterns including activated lymphocytes [8, 14],
and that both proteins act as adhesion molecules in vitro
[6, 7], one might hypothesize similar functions in cell
adhesion in vivo.
Mader expression was observed in nearly one quarter
of neurons identified by anti-NSE. Additionally, there
were some NSE-negative parenchymal cells, possibly glial
cells, reacting with anti-Mader. Mader is a nuclear protein
involved in the regulation of gene expression. It contains a
nuclear localization signal and it can be found in both the
cytoplasm and in the nucleus [9]. While Mader mRNA is
ubiquitously expressed, the protein was not detectable in
normal skin, lymph nodes and gastrointestinal tissue [9].
Our finding that Mader protein is present in normal CNS
tissue represents the first example of normal tissue ex-
pressing detectable protein levels. This is consistent with
our initial hypothesis that melanoma-associated proteins
may also be expressed in normal brain tissue. Recently,
a negative regulator of the transcription factor Egr-1
(NAB-2) has been shown to be identical to Mader [10].
Egr-1 is an immediate early response gene controlling
transcription, either positively or negatively, of a wide
range of genes involved in cell proliferation and differen-
tiation [26]. Regarding the high levels of Mader in normal
brain, its high expression in melanoma cells would appear
paradoxical. However, abnormally high levels of another
transcriptional regulator in a number of malignant tumors
[27, 28], p53, are due to mutations rendering it dysfunc-
tional [29].
Our observation that the two melanoma-associated
proteins MUC18/MCAM (CD146) and Mader are also
detectable in normal human brain tissue enables the
description of novel markers of neoplastic processes in
normal CNS prior to malignant transformation. Func-
tional analysis of these proteins has to be done to clarify
their possible roles in cell adhesion and proliferation con-
trol within the CNS.
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